Critical reviews in oncology/hematology最新文献

{"title":"Molecular features and clinical actionability of gene fusions in colorectal cancer","authors":"Francesco Giulio Sullo ,&nbsp;Simon Garinet ,&nbsp;Hélène Blons ,&nbsp;Julien Taieb ,&nbsp;Pierre Laurent-Puig ,&nbsp;Claire Gallois","doi":"10.1016/j.critrevonc.2025.104656","DOIUrl":"10.1016/j.critrevonc.2025.104656","url":null,"abstract":"<div><div>Colorectal cancer (CRC) is the third leading cause of cancer death and accounts for 10 % of cancer diagnoses worldwide. Despite the advancements achieved over the latest decades, CRC treatments are still based on conventional chemotherapy whose efficacy is limited by acquired resistance and unfavorable toxicity profile, making the search for novel actionable targets a priority. In this context, gene fusions are emerging as promising -albeit very rare - new markers because of their recurrence across different tumor types and their potential actionability. The aim of this review is to investigate the role of gene fusions in CRC by focusing on pathogenesis, screening strategies as well as their clinical implications.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"208 ","pages":"Article 104656"},"PeriodicalIF":5.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review","authors":"Federica Pecci ,&nbsp;Valeria Cognigni ,&nbsp;Giulia Claire Giudice ,&nbsp;Francesco Paoloni ,&nbsp;Luca Cantini ,&nbsp;Kamal S. Saini ,&nbsp;Hassan Mohammed Abushukair ,&nbsp;Abdul Rafeh Naqash ,&nbsp;Alessio Cortellini ,&nbsp;Giulia Mazzaschi ,&nbsp;Sonila Alia ,&nbsp;Valentina Membrino ,&nbsp;Elisa Araldi ,&nbsp;Marcello Tiseo ,&nbsp;Sebastiano Buti ,&nbsp;Arianna Vignini ,&nbsp;Rossana Berardi","doi":"10.1016/j.critrevonc.2025.104654","DOIUrl":"10.1016/j.critrevonc.2025.104654","url":null,"abstract":"<div><div>Cholesterol and its metabolism seem to be involved not only in cancer progression but also in immune cells activity. In this comprehensive review, we summarize preclinical, translational, and clinical evidence regarding the crucial role of cholesterol and its metabolism in regulating the immune response against cancer cells, shedding light on the multifaceted mechanisms by which cholesterol influences immune cell function and anti-tumor immunity. By synthesizing findings from preclinical studies, we have elucidated the impact of cholesterol on immune cell activation, differentiation, and effector functions. These investigations have revealed that cholesterol metabolism plays a pivotal role in shaping the immune response, with alterations in cholesterol levels directly impacting immune cell behavior and anti-tumor activity. All the steps related to cholesterol metabolism, including its de-novo synthesis, its influx and efflux mechanisms, as well as its metabolites, have a distinct impact on immune cells function and activity, which, if altered, might influence tumor progression. In addition, we have reviewed clinical studies investigating the role of circulating cholesterol on outcomes of patients with advanced tumors treated with immune checkpoint inhibitors, highlighting again in a clinical scenario the correlation between cholesterol and the immune system. Overall, our review emphasizes the importance of cholesterol and its metabolism in orchestrating the immune response against cancer cells. Herein we have provided a comprehensive overview of this emerging field by illustrating the intricate interplay between cholesterol and immune system.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104654"},"PeriodicalIF":5.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic cross-talk between glioblastoma and glioblastoma-associated microglia/macrophages: From basic insights to therapeutic strategies","authors":"Yuan Gao ,&nbsp;Mengxia Zhang ,&nbsp;Guihua Wang ,&nbsp;Weiwei Lai ,&nbsp;Shuxian Liao ,&nbsp;Yao Chen ,&nbsp;Qian Ning ,&nbsp;Shengsong Tang","doi":"10.1016/j.critrevonc.2025.104649","DOIUrl":"10.1016/j.critrevonc.2025.104649","url":null,"abstract":"<div><div>Glioblastoma (GBM), a highly malignant “cold” tumor of the central nervous system, is characterized by its ability to remodel the GBM immune microenvironment (GME), leading to significant resistance to immunotherapy. GBM-associated microglia/macrophages (GAMs) are essential components of the GME. Targeting GAMs has emerged as a promising strategy against GBM. However, their highly immunosuppressive nature contributes to GBM progression and drug resistance, significantly impeding anti-GBM immunotherapy. Accumulating evidence suggests that metabolic reprogramming accompanies GBM progression and GAM polarization, which are in turn driven by specific metabolic abnormalities and altered cellular signaling pathways. Importantly, metabolic crosstalk between GBM and GAMs further promotes tumor progression. Clarifying and disrupting this metabolic crosstalk is expected to enhance the antitumor phenotype of GAMs and inhibit GBM malignant progression. This review explores metabolism-based interregulation between GBM and GAMs and summarizes recent therapeutic strategies targeting this crosstalk, offering new insights into GBM immunotherapy.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"208 ","pages":"Article 104649"},"PeriodicalIF":5.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations","authors":"Carla Colombo ,&nbsp;Simone De Leo ,&nbsp;Ilaria Campisi ,&nbsp;Erica Palesandro ,&nbsp;Fabio Turco ,&nbsp;Consuelo Buttigliero ,&nbsp;Laura Fugazzola ,&nbsp;Marcello Tucci","doi":"10.1016/j.critrevonc.2025.104627","DOIUrl":"10.1016/j.critrevonc.2025.104627","url":null,"abstract":"<div><div>Nowadays immune-based combinations are the standard first-line treatment for metastatic renal cell carcinoma and involve the use of either two immunotherapy agents or an immunotherapeutic drug associated with a tyrosine kinase inhibitor. Treatment-related toxicity is the primary cause of drug discontinuation or dose reduction. A thorough understanding of the prevention and management of adverse events of the immune-based combinations is critical to ensure the success of treatment. Endocrinological toxicities during treatment with immune-based combinations are frequent and often manageable. However, in some cases, diagnosis can be complex, and the treatment requires multidisciplinary discussion. In addition, it is often challenging to determine which agent in the combination is responsible for a specific toxicity. In this review, we analyze the evidence regarding treatment-related endocrinopathies in renal cell carcinoma first-line therapy. We also discuss monitoring strategies to diagnose endocrinological adverse events and provide some practical tools for their daily management.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"209 ","pages":"Article 104627"},"PeriodicalIF":5.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating microRNAs: A remarkable opportunity as non-invasive biomarkers from adult to pediatric brain tumor patients","authors":"Federica D’Antonio ,&nbsp;Zaira Spinello ,&nbsp;Lavinia Bargiacchi ,&nbsp;Elena Splendiani ,&nbsp;Sabrina Rossi ,&nbsp;Laura Masuelli ,&nbsp;Angela Mastronuzzi ,&nbsp;Franco Locatelli ,&nbsp;Elisabetta Ferretti ,&nbsp;Giuseppina Catanzaro","doi":"10.1016/j.critrevonc.2025.104650","DOIUrl":"10.1016/j.critrevonc.2025.104650","url":null,"abstract":"<div><div>Central nervous system (CNS) tumors represent the most frequent solid tumors among adolescents and children, and the leading cause of cancer-related death in men &lt; 40 and women &lt; 20 years of age. Brain tumors are challenging to diagnose, monitor, and treat. The current diagnostic approach involves magnetic resonance imaging (MRI), tumor histology, molecular characterization and cytologic analysis of cerebrospinal fluid (CSF). However, surgical procedures pose potential risks to the patient's health, not achieving good accuracy. For these reasons, it is crucial to identify new non-invasive disease biomarkers to improve patients’ stratification at diagnosis and during follow-up and prognosis. MicroRNAs (miRNAs) are a class of short RNA molecules that have been demonstrated in numerous studies to be dysregulated in brain tumor patients. As a result, they may be used as biomarkers of brain tumors. Additionally, miRNAs can be analyzed in liquid biopsy samples, such as blood and CSF, providing a non-invasive source of biomolecular data on patients' disease status. This review aims to highlight the role of miRNAs in liquid biopsy, also known as circulating miRNAs, as potential non-invasive cancer biomarkers in both adult and pediatric populations and to suggest their potential impact on clinical trials.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"208 ","pages":"Article 104650"},"PeriodicalIF":5.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent insights and applications of nanocarriers-based drug delivery systems for colonic drug delivery and cancer therapy: An updated review","authors":"Sobia Noreen ,&nbsp;Irsah Maqbool ,&nbsp;Anum Saleem ,&nbsp;Hassan Mahmood ,&nbsp;Nadia Rai","doi":"10.1016/j.critrevonc.2025.104646","DOIUrl":"10.1016/j.critrevonc.2025.104646","url":null,"abstract":"<div><div>Colorectal cancer (CRC) is the third most prevalent malignant tumor globally and is associated with high morbidity and mortality rates. The advancement of novel nanocarrier-based drug delivery systems has revolutionized therapeutic strategies for colonic drug delivery and cancer treatment. This review provides updated insights into various nanocarrier technologies, including quantum dots (QDs), polymeric nanoparticles (PNPs), magnetic and metallic nanoparticles, solid lipid nanoparticles (SLNs), and self-microemulsifying and self-nanoemulsifying drug delivery systems (SMEDDS/SNEDDS). These nanocarriers offer enhanced drug stability, controlled release, and targeted delivery, particularly for CRC treatment, resulting in up to 70 % improved therapeutic efficacy and a significant reduction in systemic toxicity as reported in preclinical studies. The review comprehensively discusses the structural composition, mechanisms of action, therapeutic potential, and imaging capabilities of these systems, with a focus on their applications in theranostics and targeted CRC therapy. For instance, polymeric nanoparticles have demonstrated a 50 % increase in bioavailability compared to conventional formulations, while QDs have enabled real-time imaging with high precision for tumor localization. Additionally, the toxicity profiles and challenges associated with these nanocarriers are critically evaluated. Despite significant progress in preclinical and clinical studies, the review highlights the need for optimizing biocompatibility, scalability, and regulatory standards to facilitate the clinical translation of these promising technologies. Emerging formulations such as graphene quantum dots and PEGylated nanoparticles have shown potential for achieving dual therapeutic and diagnostic applications with fewer adverse effects. Overall, nanocarrier-based systems hold great potential for personalized and more effective treatments in colon-targeted therapies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"208 ","pages":"Article 104646"},"PeriodicalIF":5.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynecomastia and its potential progression to male breast cancer: Mechanisms, genetic factors, and hormonal interactions","authors":"Dingyi Fu ,&nbsp;Haoquan Miao ,&nbsp;Zhonglin Wang ,&nbsp;Chuang Yang","doi":"10.1016/j.critrevonc.2025.104651","DOIUrl":"10.1016/j.critrevonc.2025.104651","url":null,"abstract":"<div><div>Gynecomastia is the most common breast condition in men, while male breast cancer remains relatively rare. This review explores the potential relationship between gynecomastia and male breast cancer, with a focus on the roles of hormonal imbalances, genetic factors, and molecular mechanisms in the progression of these conditions. While it remains controversial whether gynecomastia is a precancerous lesion for male breast cancer, this review summarizes the roles of estrogen and androgen receptors, the regulation of aromatase expression, and mutations in key genes such as BRCA1/2. These insights point to possible pathways by which gynecomastia could transition into male breast cancer. Additionally, hormones such as prolactin, insulin-like growth factor-1, and leptin may play significant roles in this progression. We provide an overview of the current understanding and identify key areas for further research, emphasizing the need for large-scale prospective studies to determine the causal relationship between gynecomastia and male breast cancer.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"208 ","pages":"Article 104651"},"PeriodicalIF":5.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143221209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation sequencing for PTEN testing in HR+/HER2˗ metastatic breast cancer","authors":"Nicola Fusco,&nbsp;Umberto Malapelle","doi":"10.1016/j.critrevonc.2025.104626","DOIUrl":"10.1016/j.critrevonc.2025.104626","url":null,"abstract":"<div><div>Molecular alterations in the Phosphoinositide 3-kinase (PI3K) pathway are key drivers of tumorigenesis and progression in hormone receptor-positive, HER2-negative (HR+/HER2 −) metastatic breast cancer (MBC). These genomic changes are actionable through targeted therapeutic agents. In particular, access to these therapies depends on accurate molecular testing of <em>PIK3CA</em>, <em>AKT1</em>, and <em>PTEN</em>. Next-generation sequencing (NGS) has emerged as a transformative diagnostic tool, offering a comprehensive analysis of PI3K pathway alterations while concurrently evaluating other actionable markers, such as <em>ESR1</em> and <em>BRCA</em>. Acknowledging its clinical importance, the European Society for Medical Oncology (ESMO) recommends NGS of tumor or plasma samples as the standard of care for patients with HR+ /HER2 − MBC. Although resource-intensive, NGS represents a significant advancement in MBC diagnostics, ensuring that therapeutic decisions are informed by a detailed and multidimensional molecular profile. This review highlights the capabilities of NGS for PI3K pathway testing in HR+ /HER2 − MBC, with a particular focus on the spectrum of <em>PTEN</em> alterations.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"207 ","pages":"Article 104626"},"PeriodicalIF":5.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive review and meta-analysis of CTC isolation methods in breast cancer","authors":"Alexey S. Rzhevskiy ,&nbsp;Guzel R. Sagitova ,&nbsp;Tamilla A. Karashaeva ,&nbsp;Andrey O. Morozov ,&nbsp;Anastasia S. Fatyanova ,&nbsp;Vlada V. Kazantseva ,&nbsp;Simon A. Joosse ,&nbsp;Andrei V. Zvyagin ,&nbsp;Majid Ebrahimi Warkini","doi":"10.1016/j.critrevonc.2024.104579","DOIUrl":"10.1016/j.critrevonc.2024.104579","url":null,"abstract":"<div><div>The application of circulating tumor cells (CTCs) as diagnostic and prognostic markers in oncology is gaining increasing importance in clinical practice. Currently, various methods exist for detecting CTCs in patients' biological fluids. This systematic review aimed to compare the efficacy of different techniques for isolating and detecting CTCs from blood, against the FDA-cleared CellSearch® technology, in breast cancer patients. We performed a systematic literature search using two databases (PubMed and the Cochrane Library) with the following terms: (\"Circulating tumor cells\" OR CTC) AND \"breast cancer\", covering the period from 2004 to April 2023. The primary outcome measured was the sensitivity, specificity, and overall accuracy of various CTC enrichment methods in comparison with the CellSearch® System. Secondary outcomes included the prognostic value of CTCs in evaluating response to treatment based on survival rates. Generally, a high level of agreement between CellSearch and other methods was observed in isolating CTCs from patients' blood with both metastatic and early-stage disease. Studies asserting the superiority of new methods over CellSearch frequently used clinically unvalidated cut-off thresholds for their patient cohorts. Additionally, these studies sometimes included different nonoverlapping patient cohorts and lacked a standardized chemotherapy treatment protocol, which could affect the quantitative changes in CTC. It is evident that methods simultaneously composed of physical and immunomagnetic approaches for CTC isolation significantly surpass CellSearch, which relies solely on the expression of specific markers on the CTCs’ surface. The count of CTCs has been established as a predictive marker in terms of clinically important parameters namely progression-free survival (PFS) and overall survival (OS). The CTC-count value was significantly correlated with PFS and OS rates.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"206 ","pages":"Article 104579"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions","authors":"Chou-Yi Hsu ,&nbsp;Harikumar Pallathadka ,&nbsp;Saade Abdalkareem Jasim ,&nbsp;Jasur Rizaev ,&nbsp;Dmitry Olegovich Bokov ,&nbsp;Ahmed Hjazi ,&nbsp;Shriya Mahajan ,&nbsp;Yasser Fakri Mustafa ,&nbsp;Beneen Husseen ,&nbsp;Mohammed Abed Jawad","doi":"10.1016/j.critrevonc.2024.104588","DOIUrl":"10.1016/j.critrevonc.2024.104588","url":null,"abstract":"<div><div>A major advance in cancer treatment has been the development and refinement of cancer immunotherapy. The discovery of immunotherapies for a wide range of cancers has revolutionized cancer treatment paradigms. Despite relapse or refractory disease, immunotherapy approaches can prolong the life expectancy of metastatic cancer patients. Multiple therapeutic approaches and agents are currently being developed to manipulate various aspects of the immune system. Oncolytic viruses, cancer vaccines, adoptive cell therapies, monoclonal antibodies, cytokine therapies, and inhibitors of immune checkpoints have all proven successful in clinical trials. There are several types of immunotherapeutic approaches available for treating cancer, and others are being tested in preclinical and clinical settings. Immunotherapy has proven successful, and many agents and strategies have been developed to improve its effectiveness. The purpose of this article is to present a comprehensive overview of current immunotherapy approaches used to treat cancer. Cancer immunotherapy advancements, emerging patterns, constraints, and potential future breakthroughs are also discussed.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"206 ","pages":"Article 104588"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}